Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces the issue of share options over ordinary shares of 0.2p each in the Company (“Share Options”) on 30 June 2020, to certain members of the Company’s senior management team and other key staff. These share options have been issued pursuant to certain contractual share-based entitlements in place prior to the IPO and are governed by the rules of the Company’s Employee Share Option Plan (“ESOP”). Share Options were granted as follows:
| Name | Number of Share Options granted | Total no. of ordinary shares under option post grant | % of existing issued share capital |
| Damian Thornton (COO and PDMR) | 4,200 | 102,704 | 0.12% |
| Jordan Clark (CTO and PDMR) | 4,200 | 76,114 | 0.09% |
| Susanne Munksted (CPO and PDMR) | 4,200 | 70,672 | 0.08% |
A further 214,500 Share Options were granted to 51 employees, each of whom received 4,200 Share Options. The Share Options vest in full after three years following date of grant. The exercise price of the Share Options is 0.2p per share being the nominal value of the share. Following the grant the total number of share options outstanding granted to the Company’s Directors, senior management team and key employees is 1,790,762, representing approximately 2.13% of the Company’s current issued share capital of 84,068,923.
| Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | ||||||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||||
| a. | Name | Damian Thornton | ||||||
| 2 | Reason for notification | |||||||
| a. | Position/Status | Chief Operating Officer | ||||||
| b. | Initial notification/ Amendment | Initial | ||||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||
| a. | Name | Diaceutics PLC | ||||||
| b. | LEI | 213800VEWQBB39ZB8J81 | ||||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||
| a. | Description of the financial instrument, type of instrument Identification Code | Options over new ordinary shares of 0.2p each ISIN: GB00BJQTGV64 | ||||||
| b. | Nature of the transaction | Grant of share options | ||||||
| c. | Price(s) and volume(s) | |||||||
| Price(s) | Volume(s) | |||||||
| Exercise price of 0.2p per share | 4,200 | |||||||
| e. | Date of the transaction | 30 June 2020 | ||||||
| f. | Place of the transaction | Outside a trading venue | ||||||
| Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | ||||||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||||
| a. | Name | Jordan Clark | ||||||
| 2 | Reason for notification | |||||||
| a. | Position/Status | Chief Technology Officer | ||||||
| b. | Initial notification/ Amendment | Initial | ||||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||
| a. | Name | Diaceutics PLC | ||||||
| b. | LEI | 213800VEWQBB39ZB8J81 | ||||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||
| a. | Description of the financial instrument, type of instrument Identification Code | Options over new ordinary shares of 0.2p each ISIN: GB00BJQTGV64 | ||||||
| b. | Nature of the transaction | Grant of share options | ||||||
| c. | Price(s) and volume(s) | |||||||
| Price(s) | Volume(s) | |||||||
| Exercise price of 0.2p per share | 4,200 | |||||||
| e. | Date of the transaction | 30 June 2020 | ||||||
| f. | Place of the transaction | Outside a trading venue | ||||||
| Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | ||||||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||||
| a. | Name | Susanne Munksted | ||||||
| 2 | Reason for notification | |||||||
| a. | Position/Status | Chief Precision Officer | ||||||
| b. | Initial notification/ Amendment | Initial | ||||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||
| a. | Name | Diaceutics PLC | ||||||
| b. | LEI | 213800VEWQBB39ZB8J81 | ||||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||
| a. | Description of the financial instrument, type of instrument Identification Code | Options over new ordinary shares of 0.2p each ISIN: GB00BJQTGV64 | ||||||
| b. | Nature of the transaction | Grant of share options | ||||||
| c. | Price(s) and volume(s) | |||||||
| Price(s) | Volume(s) | |||||||
| Exercise price of 0.2p per share | 4,200 | |||||||
| e. | Date of the transaction | 30 June 2020 | ||||||
| f. | Place of the transaction | Outside a trading venue | ||||||
